Drug profile · INN
lisinopril
APO-LISINOPRIL
lisinopril (APO-LISINOPRIL) is a angiotensin-converting enzyme inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — lisinopril
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
lisinopril (APO-LISINOPRIL) is a angiotensin-converting enzyme inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Angiotensin-converting enzyme inhibitor
Primary target: Angiotensin-converting enzyme
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lisinopril?
lisinopril (APO-LISINOPRIL) is a angiotensin-converting enzyme inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lisinopril?
APO-LISINOPRIL is a marketed brand name for lisinopril. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lisinopril?
lisinopril has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.